Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- McLaren Cancer Institute-Bay City — Bay City, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…
Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in Michigan: - University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
- Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…
Sponsor: Eli Lilly and Company
NCT ID: NCT07218380
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
- Brigitte Harris Cancer Pavilion — Detroit, Michigan
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06319820
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
- Comprehensive Urology — Royal Oak, Michigan
Phase 2, Phase 3 Recruiting Industry
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07106762
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 2, Phase 3 Recruiting Industry
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizu…
Sponsor: Daiichi Sankyo
NCT ID: NCT07129993
Sites in Michigan: - Research Site — Grand Rapids, Michigan
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Gué…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06919965
Sites in Michigan: - Comprehensive Urology — Royal Oak, Michigan
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
Phase 2 Recruiting Industry
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04879329
Sites in Michigan: - The Cancer & Hematology Centers — Big Rapids, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) — Detroit, Michigan
- Karmanos Cancer Institute Weisberg Cancer Treatment Center — Farmington Hills, Michigan
- The Cancer & Hematology Centers — Grand Rapids, Michigan
Phase 2 Recruiting NIH
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunothe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06770582
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Canton — Canton, Michigan
- Chelsea Hospital — Chelsea, Michigan
- University of Michigan Health - Sparrow Lansing — Lansing, Michigan
Phase 2 Recruiting Industry
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Sponsor: CG Oncology, Inc.
NCT ID: NCT06567743
Sites in Michigan: - Comprehensive Urology — Royal Oak, Michigan
- Michigan Institute of Urology (Solaris) — Troy, Michigan
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establis…
Sponsor: enGene, Inc.
NCT ID: NCT04752722
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
- Corewell Health Medical Group and Spectrum Health Hospitals — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Michigan: - START Midwest — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in co…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in Michigan: - START Midwest — Grand Rapids, Michigan
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Michigan: - Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit — Detroit, Michigan
- Profound Research -OMG - TriAtria Cancer Center — Farmington Hills, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and …
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06800963
Sites in Michigan: - Michigan Institute of Urology & Solaris Health — Troy, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibi…
Sponsor: Medicenna Therapeutics, Inc.
NCT ID: NCT05086692
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 2 Recruiting Academic/Other
This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based therapy. Cisplatin-based …
Sponsor: Yuanquan Yang
NCT ID: NCT06263153
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
Phase 1 Recruiting Industry
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cel…
Sponsor: Eli Lilly and Company
NCT ID: NCT05614739
Sites in Michigan: - Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Michigan: - START Midwest — Grand Rapids, Michigan
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
- Henry Ford Cancer Institute — Detroit, Michigan
- START - Midwest Cancer Research Center — Grand Rapids, Michigan
Phase 1 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase…
Sponsor: Eli Lilly and Company
NCT ID: NCT06465069
Sites in Michigan: - START Midwest Cancer and Hematology Centers of W Michigan — Grand Rapids, Michigan
Phase 1 Recruiting Industry
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Michigan: - BAMF Health — Grand Rapids, Michigan